NuVasive, Inc. (NASDAQ:NUVA) insider Matthew Link sold 2,582 shares of the company’s stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $62.02, for a total value of $160,135.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Matthew Link also recently made the following trade(s):

  • On Friday, November 16th, Matthew Link sold 1,200 shares of NuVasive stock. The stock was sold at an average price of $62.01, for a total value of $74,412.00.

Shares of NUVA traded up $0.62 during midday trading on Wednesday, reaching $62.12. 33,707 shares of the stock were exchanged, compared to its average volume of 803,705. NuVasive, Inc. has a 52 week low of $44.62 and a 52 week high of $72.41. The company has a current ratio of 3.45, a quick ratio of 1.83 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 1.84 and a beta of 0.78.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Tuesday, October 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.06). NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The firm had revenue of $271.30 million for the quarter, compared to the consensus estimate of $265.70 million. During the same period in the previous year, the company posted $0.52 EPS. NuVasive’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts predict that NuVasive, Inc. will post 2.18 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Anchor Capital Advisors LLC boosted its position in NuVasive by 1,205.1% during the second quarter. Anchor Capital Advisors LLC now owns 983,977 shares of the medical device company’s stock valued at $51,285,000 after purchasing an additional 908,582 shares in the last quarter. Hood River Capital Management LLC boosted its position in NuVasive by 261.3% during the second quarter. Hood River Capital Management LLC now owns 866,653 shares of the medical device company’s stock valued at $45,170,000 after purchasing an additional 626,770 shares in the last quarter. Victory Capital Management Inc. boosted its position in NuVasive by 100.0% during the third quarter. Victory Capital Management Inc. now owns 1,000,605 shares of the medical device company’s stock valued at $71,023,000 after purchasing an additional 500,395 shares in the last quarter. Redmile Group LLC bought a new stake in NuVasive during the third quarter valued at about $31,210,000. Finally, Investment Counselors of Maryland LLC bought a new stake in NuVasive during the third quarter valued at about $21,782,000.

Several research firms have weighed in on NUVA. Zacks Investment Research upgraded NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, August 21st. BidaskClub upgraded NuVasive from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. ValuEngine upgraded NuVasive from a “strong sell” rating to a “sell” rating in a report on Monday, July 30th. BTIG Research increased their price target on NuVasive to $72.00 and gave the company a “buy” rating in a report on Thursday, August 16th. Finally, TheStreet upgraded NuVasive from a “c+” rating to a “b-” rating in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. NuVasive has a consensus rating of “Hold” and an average target price of $67.47.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/21/nuvasive-inc-nuva-insider-matthew-link-sells-2582-shares.html.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Recommended Story: Do You Need a Fiduciary?

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.